Literature DB >> 8240013

Raccoon poxvirus rabies virus glycoprotein recombinant vaccine in sheep.

J C DeMartini1, H M Bickle, S J Brodie, B X He, J J Esposito.   

Abstract

Twenty sheep were divided into groups and inoculated by various routes with recombinant raccoon poxvirus expressing the CVS rabies virus glycoprotein (rRCNV-G) or with raccoon poxvirus (RCNV). The apparent innocuous pathologic responses to each virus coupled with development of high levels of rabies virus neutralizing antibodies in animals vaccinated with rRCNV-G intradermally or intramuscularly suggested that the recombinant is effective and that RCNV would be a suitable substrate for further development of sheep vaccines. Poor antibody response to rRCNV-G given orally implied that it would be relatively harmless if inadvertently ingested by sheep. Virus transmission between vaccinated and sentinel sheep was not observed or detected serologically.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8240013     DOI: 10.1007/bf01309757

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  22 in total

1.  The protective role of humoral neutralizing antibody in the NIH potency test for rabies vaccines.

Authors:  P S Wunderli; J H Shaddock; D S Schmid; T J Miller; G M Baer
Journal:  Vaccine       Date:  1991-09       Impact factor: 3.641

2.  Survey of wild mammals in a Chesapeake Bay area for selected zoonoses.

Authors:  A D Alexander; V Flyger; Y F Herman; S J McConnell; N Rothstein; R H Yager
Journal:  J Wildl Dis       Date:  1972-04       Impact factor: 1.535

3.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype.

Authors:  R M Buller; G L Smith; K Cremer; A L Notkins; B Moss
Journal:  Nature       Date:  1985 Oct 31-Nov 6       Impact factor: 49.962

4.  A rapid tissue culture test for determining rabies neutralizing antibody.

Authors:  J S Smith; P A Yager; G M Baer
Journal:  Monogr Ser World Health Organ       Date:  1973

5.  Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine.

Authors:  B Brochier; M P Kieny; F Costy; P Coppens; B Bauduin; J P Lecocq; B Languet; G Chappuis; P Desmettre; K Afiademanyo
Journal:  Nature       Date:  1991 Dec 19-26       Impact factor: 49.962

6.  Effects of virus load in the pathogenesis of lentivirus-induced lymphoid interstitial pneumonia.

Authors:  S J Brodie; K A Marcom; L D Pearson; B C Anderson; A de la Concha-Bermejillo; J A Ellis; J C DeMartini
Journal:  J Infect Dis       Date:  1992-09       Impact factor: 5.226

7.  Expression of rabies virus glycoprotein from a recombinant vaccinia virus.

Authors:  M P Kieny; R Lathe; R Drillien; D Spehner; S Skory; D Schmitt; T Wiktor; H Koprowski; J P Lecocq
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

8.  Response of dairy calves to vaccinia viruses that express foreign genes.

Authors:  J H Gillespie; C Geissinger; F W Scott; W P Higgins; D F Holmes; M Perkus; S Mercer; E Paoletti
Journal:  J Clin Microbiol       Date:  1986-02       Impact factor: 5.948

9.  Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.

Authors:  J F Rooney; C Wohlenberg; K J Cremer; B Moss; A L Notkins
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

10.  Efficacy of a vaccinia-rabies glycoprotein recombinant virus vaccine in raccoons (Procyon lotor).

Authors:  C E Rupprecht; A N Hamir; D H Johnston; H Koprowski
Journal:  Rev Infect Dis       Date:  1988 Nov-Dec
View more
  6 in total

1.  Protection of black-tailed prairie dogs (Cynomys ludovicianus) against plague after voluntary consumption of baits containing recombinant raccoon poxvirus vaccine.

Authors:  Jordan S Mencher; Susan R Smith; Tim D Powell; Dan T Stinchcomb; Jorge E Osorio; Tonie E Rocke
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

2.  Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.

Authors:  Laura Evgin; Markus Vähä-Koskela; Julia Rintoul; Theresa Falls; Fabrice Le Boeuf; John W Barrett; John C Bell; Marianne M Stanford
Journal:  Mol Ther       Date:  2010-02-16       Impact factor: 11.454

Review 3.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

4.  Oncolytic properties of non-vaccinia poxviruses.

Authors:  Marine Ricordel; Johann Foloppe; Christelle Pichon; Annie Findeli; Caroline Tosch; Pascale Cordier; Sandrine Cochin; Eric Quémeneur; Christelle Camus-Bouclainville; Stéphane Bertagnoli; Philippe Erbs
Journal:  Oncotarget       Date:  2018-11-13

5.  Virally-vectored vaccine candidates against white-nose syndrome induce anti-fungal immune response in little brown bats (Myotis lucifugus).

Authors:  Tonie E Rocke; Brock Kingstad-Bakke; Marcel Wüthrich; Ben Stading; Rachel C Abbott; Marcos Isidoro-Ayza; Hannah E Dobson; Lucas Dos Santos Dias; Kevin Galles; Julia S Lankton; Elizabeth A Falendysz; Jeffrey M Lorch; J Scott Fites; Jaime Lopera-Madrid; J Paul White; Bruce Klein; Jorge E Osorio
Journal:  Sci Rep       Date:  2019-05-01       Impact factor: 4.996

6.  Infectivity of attenuated poxvirus vaccine vectors and immunogenicity of a raccoonpox vectored rabies vaccine in the Brazilian Free-tailed bat (Tadarida brasiliensis).

Authors:  Ben R Stading; Jorge E Osorio; Andres Velasco-Villa; Michael Smotherman; Brock Kingstad-Bakke; Tonie E Rocke
Journal:  Vaccine       Date:  2016-09-17       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.